International Conference on Population and Development

• People’s physical and mental health were severely impacted by the sudden changes forced by the emergent global crisis.
• Although global movements and organizations are dedicated to supporting universities’ work in health promotion, and many universities have committed to doing so, our research indicates that campuses struggle to promote health in a meaningful way.

Health promotion in universities

• The movement to see universities promoting health was initially championed by the UK Healthy Universities Network.
• 5 ways university students and faculty hope for better

  The framework was developed at the 2015 International Conference on Health Promoting Universities and Colleges held in Kelowna, B.C.

Health in all aspects of campus culture

• The Okanagan Charter calls for embedding health into all aspects of campus culture and leading health promotion action and collaboration.
• The Canadian Health Promoting Campuses Network assists Canadian campuses in the adoption of the charter.
• All of these national networks are connected up to the International Health Promoting Universities and campuses.

Challenges with implementation

• As the Okanagan Charter nears its 10th anniversary, questions remain about its limited adoption, its challenges with implementation and the progress made towards its calls to action.
• Our research project, funded by the Social Sciences and Humanities Research Council, examined the adoption, implementation and evaluation of the charter at the first 10 Canadian campuses who signed onto the charter in 2016 and 2017: University of British Columbia, University of Saskatchewan, Simon Fraser University, University of Guelph, Mount Royal University, King’s University College, University of Lethbridge, Western University, University of Calgary and Memorial University.

Implementation left to a few people

• The research uncovered that many of the first signatory campuses were struggling with taking action on many of their Charter commitments.
• In many cases, after executive leadership signed the charter, the implementation was left to a few people working with few resources to design initiatives and follow progress.

Evaluation absent

• Evaluation and assessment frameworks were especially absent at most campuses.
• That finding has lead to our renewed concern: how are universities evaluating progress against broader health goals?

Well-resourced approaches

• Universities need to work towards engaged leadership, deliberate actions, innovative and well-resourced approaches, networked opportunities and meaningful measures of progress.
• If university leaders say that this work matters, that means they must elevate the profile of health and well-being on campus.
• Some identifiable next steps can be: 1) Embed well-being in institutional strategic plans.
• 3) Give stewards of the work resources, both financial and human, for relevant activities and initiatives.

• InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company, today announced the latest clinical data of its Bruton Tyrosine Kinase (BTK) inhibitor orelabrutinib at the 17th International Conference on Malignant Lymphoma (ICML).
• Among the enrolled Chinese patients, the majority had late-stage diseases, with the stage IV accounting for 75.9%.
• The 12-month PFS rate was 84.3% and the rate of overall survival (OS) was 91.5% at 12 months.
• The preliminary data indicated that the orelabrutinib plus lenalidomide and rituximab exerted synergistic antitumor activity, with a good safety profile in the treatment of MCL.

• Data results will be presented at the 17th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland June 13-17.
• The study will be presented on June 17, 2023.
• Immune-mediated AEs observed to date are consistent with the individual safety profile of nivolumab.
• Please see Important Safety Information, including a BOXED WARNING for progressive multifocal leukoencephalopathy (PML), for ADCETRIS below.

• Bristol Myers Squibb (NYSE: BMY) today announced results from a Phase 2 study evaluating BMS-986278, a potential first-in-class, oral, lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis.
• Pulmonary fibrosis is a devastating, life-threatening illness, with daily symptoms including coughing, labored breathing and extreme fatigue.
• Dose reductions due to blood pressure criteria were implemented in 5% (placebo), 8% (30 mg) and 6% (60 mg) of patients.
• A similar number of patients received dose reduction across the placebo (n=5), 30 mg (n=7) and 60 mg (n=6) treatment arms.